Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 23, 2006

Connetics and Stiefel to Merge

  • Connetics signed a definitive merger agreement with Stiefel Laboratories. Upon the closing of the transaction, holders of Connetics’ common stock will receive $17.50 per share in cash, representing a 62% premium to Connetics' average closing price for the past four weeks. The aggregate value to be received by Connetics' stockholders is approximately $640 million.

    After the combination, which the companies expect will occur in late 2006 or early 2007, Stiefel Laboratories will have more than 3,500 employees worldwide with more than 30 subsidiaries and sales in more than 100 countries.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »